Expert Perspectives 2024: The Dynamic Future of Obesity Medicine, with Donna Ryan, MD

In this Patient Care© year-end video series we feature interviews with leading physician scientists and principal investigators who discuss the most important clinical trials of the year with experimental drugs, devices, and procedures, the implications of findings for daily primary care practice, and the promise of these unique additions to patient care.

Welcome to Expert Perspectives 2024: Interviews with Key Opinion Leaders on Novel Therapeutics

In the interview series that begins with the video above, Donna Ryan, MD, professor emerita at the Pennington Biomedical Research Center in Baton Rouge, LA, discusses groundbreaking obesity research from 2024 and what is to come in 2025. In this first video, Pivotal Obesity Trials in 2024: A Conversation with Donna Ryan, MD (above), Ryan highlights pivotal trials that showed how GLP-1 receptor agonists (ie, semaglutide) and dual agonists (ie, tirzepatide) are redefining obesity treatment by addressing chronic disease management.

Following are links to the rest of the series:

The Evolving Perception and Utilization of Antiobesity Drugs: Expert Discussion

Emerging Obesity Research to Watch For in 2025

Future of Obesity Care: 3 Wishes from Thought Leader Donna Ryan, MD